Search Results
Your search for ASCO matches 21351 pages
Showing 18551 - 18600Beyond R-CHOP for Lymphoma
The R-CHOP regimen (rituximab [Rituxan] plus cyclophosphamide, doxorubicin, vincristine, and prednisone) was a major advance in treating diffuse large B-cell lymphoma, but experts are seeking to up the ante and identify ways to continue to improve outcomes beyond that achieved with R-CHOP. “We are...
MD Anderson Receives $5 Million Grant for Research in Glioblastoma
The Broach Foundation for Brain Cancer Research has made a $5 million commitment to support glioblastoma multiforme research at The University of Texas MD Anderson Cancer Center in Houston. James and Jamie Broach established the Broach Foundation in 2011, just months after Mr. Broach was diagnosed...
NIH 2014 New Innovator Award Recipient Pamela Kreeger, PhD, to Study Metastasis in Ovarian Cancer
Pamela Kreeger, PhD, Assistant Professor of Biomedical Engineering at the University of Wisconsin-Madison, is among a group of researchers to receive a 2014 New Innovator Award from the National Institutes of Health. Dr. Kreeger will receive funding of nearly $2.3 million. She has chosen to study...
Variety of Adjuvant Strategies Explored in HER2‑Positive and Other Breast Cancer Types
Adjuvant trastuzumab (Herceptin) was shown to be effective in patients with breast cancers ≤ 2 cm, regardless of estrogen receptor status, in a meta-analysis1 of five chemotherapy trials, but a “pressing question” remaining is whether T1a/b, N0 tumors warrant the use of adjuvant trastuzumab, Andrew ...
50 Years of Advancements in Treating Breast Cancer Have Led to Tumor-Centered Treatment Algorithm
Transformations in the treatment of early-stage breast cancer have shifted the therapeutic approach from a “stage-centered treatment algorithm” to a “tumor biology-centered treatment algorithm,” Priyanka Sharma, MD, Associate Professor of Medicine, University of Kansas School of Medicine, Kansas...
For Triple-Negative Breast Cancer, Adding Carboplatin to Anthracycline/Taxane Produces Benefit, but How Much?
Combination chemotherapy for triple-negative breast cancer is anthracycline- and taxane-based and has not really changed much in the past 10 years, but “we are starting to see emerging data with selective activity of platinum agents,” Priyanka Sharma, MD, told participants at the Best of ASCO...
Latest Patient Booklet From ASCO and Cancer.Net: Palliative Care
ASCO Answer’s new Palliative Care booklet teaches patients and their families about this specialized area of medicine, explaining the difference between palliative care and hospice care and how palliative care is more than receiving a drug to ease physical symptoms. The booklet also includes...
ASCO Recruits Members to Help Improve Access to Colorectal Cancer Screening, Follow-up Care
ASCO is among the medical professional societies supporting the National Colorectal Cancer Roundtable (NCCRT) by recruiting physician leaders from within its membership for a pilot program called Links of Care. The program was established to promote health equity and to improve access to colorectal ...
CancerLinQ™ Receives Major Commitment From CTCA®
The Conquer Cancer Foundation of ASCO has received a major commitment of support for the development of CancerLinQ™ from Cancer Treatment Centers of America, Inc (CTCA), a national network of five cancer hospitals. The donation is the largest received to date in support of CancerLinQ, a...
Illumination and Innovation: Transforming Data Into Learning
"Illumination” is a provocative word, evoking as it does the banishment of the darkness of ignorance by the light of new knowledge. Today, we are benefiting from a steady stream of new knowledge about the molecular basis of cancer and the interaction between host and tumor immunology. The concept...
Progress Against Cancer: A Snapshot
Five decades ago, cancer was viewed as a monolithic and largely untreatable disease, with only a handful of hard-to-tolerate and mostly ineffective therapies available. Since that time, major U.S. investments in cancer research have led to dramatic improvements in our biologic understanding of...
Despite Potential to Overwhelm, Surveys Still Essential Research Tool
The age of the Internet and worldwide connectivity has made it easier than ever to send out surveys to a wide audience quickly and easily. This ease of access can make surveys an affordable and readily available research tool for independent investigators, but it can also make surveys an...
Lenvatinib Receives Priority Review Designation for Advanced Thyroid Cancer
The U.S. Food and Drug Administration (FDA) has given Priority Review designation to the New Drug Application for lenvatinib mesylate as a treatment for progressive radioactive iodine–refractory differentiated thyroid cancer. Lenvatinib is an oral multiple receptor tyrosine kinase inhibitor with a...
E-Cigarettes Unhelpful in Smoking Cessation Among Patients With Cancer
In a new study of patients with cancer who smoke, those using e-cigarettes in addition to traditional cigarettes were more nicotine-dependent and equally or less likely to have quit smoking traditional cigarettes than nonusers.1 The rising use of e-cigarettes has raised many questions among...
Peter Carroll, MD, MPH, Receives Grant for Early Detection of Prostate Cancer
The ZERO Cancer Research Fund has awarded the Jim Lafferty Memorial Research Grant in the amount of $45,000 to Peter Carroll, MD, MPH, of the University of California San Francisco, for the purpose of researching new and improved methods for early detection of prostate cancer. The grant is part of...
Blinatumomab Receives FDA Priority Review Designation in Acute Lymphoblastic Leukemia
The U.S. Food and Drug Administration (FDA) has accepted for review Amgen’s Biologics License Application for blinatumomab for the treatment of adults with Philadelphia chromosome–negative relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). As part of the acceptance, the FDA granted ...
FDA Approves Netupitant and Palonosetron Combination Capsule for Chemotherapy-Induced Nausea and Vomiting
The U.S. Food and Drug Administration (FDA) has approved a combination of netupitant and palonosetron (Akynzeo) to treat nausea and vomiting in patients undergoing cancer chemotherapy. The new drug, also known as NEPA, is a fixed-combination capsule comprised of two agents: oral palonosetron, which ...
FDA Approves Bortezomib Injection for Previously Untreated Patients With Mantle Cell Lymphoma
The U.S. Food and Drug Administration (FDA) has approved bortezomib (Velcade) injection for previously untreated patients with mantle cell lymphoma. This is the first treatment in the United States to be approved for use in previously untreated patients with mantle cell lymphoma. Bortezomib was...
Novel Oral Agent Treats Cachexia in Patients With Non–Small Cell Lung Cancer
For the first time, studies show that a drug is effective in treating several domains of cancer-related cachexia. Oral anamorelin increased lean body mass, achieved weight gain, and improved quality of life in patients with cancer-related cachexia in two pivotal phase III studies presented together ...
Women Underrepresented in Oncology Leadership Positions, Greek Survey Shows
A growing number of oncologists in Greece are female, but women continue to be underrepresented in leadership positions, according to a survey reported at the ESMO 2014 Congress. “In Greece, and across Europe, women oncologists still find it hard to access leadership or academic positions,” said...
Expert Point of View: Christian Blank, MD, PhD
Oncologists are now “in the luxury position of having two highly potent agents to treat BRAF V600–mutated melanoma,” noted Christian Blank, MD, PhD, Group Leader of Immunology at The Netherlands Cancer Institute, Amsterdam, who discussed the two papers at the ESMO 2014 Presidential Symposium....
Practice-Changing Results at ESMO 2014
A record number of 19,859 attendees at the European Society for Medical Oncology (ESMO) 2014 Congress discussed changes to oncology that will soon have a positive impact on the care of patients around the world. “We are particularly pleased to see participants from 131 countries at the congress...
UCSF Study Finds $18 Billion Tobacco Toll in California, 2009
Smoking took an $18.1 billion toll in California in 2009—$487 for each resident—and was responsible for more than one in seven deaths in the state, more than from AIDS, influenza, diabetes, or many other causes, according to the first comprehensive analysis in more than a decade on the financial...
BRCA Mutations Found in Many Breast Tumors Called ‘ER-Positive’
BRCA mutations may occur in nearly one-third of breast cancer patients who would have been described as having triple-negative cancer except that their tumors express low levels of estrogen receptor, so the tumors are described as ER–low positive, according to researchers from The University of...
What Is the Real Risk of Breast Cancer Associated With Atypical Hyperplasia?
Women with atypical hyperplasia have an absolute risk of about 1% per year for developing breast cancer—a level of risk that has been underappreciated. Not enough is being done to protect these women, according to Lynn C. Hartmann, MD, Professor of Oncology at the Mayo Clinic in Rochester,...
Novel Agents May Address Endocrine Therapy Resistance
Progress has recently been swift in the development of new drugs to improve the response to hormone therapy in breast cancer, according to Hope S. Rugo, MD, Professor of Medicine and Director of Breast Oncology and Clinical Trials Education at the University of California, San Francisco, Helen...
Partnering With Community Centers to Advance Oncology Care
Last fall, Richard R. Barakat, MD, FACS, the Ronald O. Perelman Chair in Gynecologic Surgery at Memorial Sloan Kettering Cancer Center, was named to the new position of Deputy Physician-in-Chief for the Memorial Sloan Kettering Regional Care Network and Cancer Alliance, a new initiative meant to...
Recent Reports and Perspectives on Chronic Lymphocytic Leukemia
Recent articles on developments and controversies in the treatment of chronic lymphocytic leukemia include the following features from The ASCO Post, which are also available at www.ascopost.com: “Recent FDA Approvals Foster Growing Treatment Armamentarium for Chronic Lymphocytic Leukemia and Rare ...
Linking Biology and Therapy in Chronic Lymphocytic Leukemia
Recent discoveries in biology, therapy, and (most importantly) the interplay between these two have led to groundbreaking advances in chronic lymphocytic leukemia (CLL). These advances underline the impact of the “translational” approach to cancer management in general. Standard of Care...
CLEOPATRA: Survival With Dual HER2 Blockade ‘Unprecedented’
In the final overall survival analysis of the phase III CLEOPATRA trial, HER2-positive metastatic breast cancer patients lived 15.7 months longer if they received pertuzumab (Perjeta) in addition to trastuzumab (Herceptin) and docetaxel, investigators reported at the European Society for Medical...
Dr. Conti Replies
Dr. Watson states that my assertion that physicians gain profit from the administration of chemotherapy in private practice is “absurd.” Recent reports from the Oncology Circle practices [a data-sharing collaborative of best-in-class oncology practices from across the country] suggest that current...
More on Chemotherapy Costs
I took exception to a number of the comments made by Rena Conti, PhD, in The ASCO Post (“Health-Care Reform Is Changing the Oncology Landscape,” October 15, 2014, page 1). I realize that The ASCO Post is not a peer-reviewed and indexed publication, but as an ASCO member, I also recognize that the...
The 2014 Nobel Prize in Physiology or Medicine Awarded to John O’Keefe, PhD, and Jointly to May-Britt Moser, PhD, and Edvard I. Moser, PhD
The 2014 Nobel Prize in Physiology or Medicine has been awarded with one half to John O’Keefe, PhD, of University College London, and the second half jointly awarded to May-Britt Moser, PhD, and Edvard I. Moser, PhD, of the Norwegian University of Science and Technology in Trondheim, for their...
Expect Questions About Pertuzumab for HER2-Positive Breast Cancer
The 56.5-month overall survival for women with HER2-positive metastatic breast cancer receiving first-line treatment with pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) and docetaxel in the CLEOPATRA trial represents a 15.7-month survival advantage for those receiving pertuzumab...
Impressive Survival Data for Women With HER2-Positive Breast Cancer Increase First-Line Use of Pertuzumab/Trastuzumab
"Impressive,” “outstanding,” and “unprecedented” are among the terms used to describe the 56.5-month overall survival for women with HER2-positive metastatic breast cancer receiving first-line treatment with pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) and docetaxel in the...
Printed NCCN Guidelines for Patients Now Available Through Amazon.com
The National Comprehensive Cancer Network (NCCN), with the support of the NCCN Foundation, recently announced the availability of printed versions of the NCCN Guidelines for Patients for order on Amazon.com for the following cancer types: Breast (Stages 0–IV), Colon, and Pancreatic Cancers;...
The Power of Laughter
The following essay by Julie Vose, MD, MBA, FASCO, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories (May 2014), coedited by Stan Winokur, MD, and Vincent Coppola. The book is available on Amazon.com and thebigcasino.org. When I met Cindy, she was...
New James Cancer Hospital in Columbus, Ohio, Opening in December 2014
In December 2014, The Ohio State University Comprehensive Cancer Center, the James Cancer Hospital and Solove Research Institute will open the doors of a new 1.1 million square foot, 21-floor freestanding cancer hospital—making Columbus, Ohio, home to the third largest cancer hospital in the United ...
2014 Oncology Meetings
NOVEMBER EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer TherapeuticsNovember 18-21 • Barcelona, SpainFor more information: www.aacr.org ESMO Symposium on Immuno-OncologyNovember 21-22 • Geneva, Switzerland For more information: www.esmo.org/Conferences/Immuno-Oncology-2014...
A Candidly Humorous Approach to the Cancer Journey
BOOKMARK Title: Shrinkage: Manhood, Marriage, and the Tumor That Tried to Kill MeAuthor: Bryan BishopPublisher: Thomas Dunne BooksPublication date: April 29, 2014Price: $25.99; hardcover, 336 pages At 30 years old, Bryan Bishop was having the time of his life. Known to millions of radio fans as...
A Father and Son’s Journey Through Medicine
BOOKMARK Title: The Good Doctor: A Father, a Son, and the Evolution of Medical EthicsAuthor: Barron H. Lerner, MDPublisher: Beacon PressPublication date: May 13, 2014Price: $25.95; hardcover, 240 pages One morning in 1996, an infectious disease specialist was making rounds when he and his team...
Martine Extermann, MD, PhD, Honored at the International Society of Geriatric Oncology’s Annual Meeting in Portugal
Martine Extermann, MD, PhD, Senior Member of the Senior Adult Oncology and Health Outcomes & Behavior Programs at Moffitt Cancer Center, was the recipient of the 2014 Paul Calabresi Award. Named after the first president of the International Society of Geriatric Oncology (SIOG), the award...
Breast Cancer Researcher to Lead Radiation Oncology at IU School of Medicine
Richard C. Zellars, MD, from the Johns Hopkins University School of Medicine has been named Professor and Chair of Radiation Oncology at the Indiana University School of Medicine, pending approval by the Indiana Univerity trustees. He will begin his new duties in January. A breast cancer...
Institute of Medicine Elects 70 New Members, 10 Foreign Associates
The Institute of Medicine (IOM) has announced the names of 70 new members and 10 foreign associates during its 44th Annual Meeting held in October. Election to the IOM is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated...
Tina Lundgren Elected Chairman of the Ronald McDonald House New York Board of Directors
Ronald McDonald House® New York announced that Tina Lundgren has been elected to serve as Chairman of its Board of Directors. Mrs. Lundgren will succeed Stanley B. Shopkorn, Managing Director of Hilltop Park Associates LLC, who has served as chairman since 2006. Mrs. Lundgren will serve a 3-year...
2014 Ellen Stovall Award Presented to Giuliana Rancic, E! News Co-Anchor and Co-Host of The Fashion Police
As part of the Lilly Oncology On Canvas Art Competition, Lilly Oncology and the National Coalition for Cancer Survivorship created the Ellen Stovall Award in honor of Ellen Stovall, a tireless advocate for cancer survivors and former president and CEO of NCCS. The award recognizes those who use...
Lilly Oncology On Canvas Art Competition Names 2014 Winners
The 10th anniversary of the Lilly Oncology On Canvas Art Competition was celebrated with the presentation of awards and display of winning entries on October 23 in New York’s Grand Central Terminal. The competition, which is presented by Lilly Oncology and National Coalition for Cancer Survivorship ...
ASCO Endorses CAP/IASLC/AMP Guidelines for Molecular Testing of Patients With Non–Small Cell Lung Cancer
Personalized medicine is an established treatment concept for patients with advanced non–small cell lung cancer (NSCLC), and molecular characterization of tumors is crucial for choice of (first-line) therapy. As of right now, we have U.S. Food and Drug Administration (FDA)-approved drugs for two...
ASCO Endorses Guideline for Molecular Testing for Selecting Lung Cancer Patients for EGFR and ALK Inhibitor Treatment
ASCO has endorsed the recently developed joint College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association for Molecular Pathology (AMP) guideline on molecular testing for selection of patients with lung cancer for EGFR and ALK inhibitor...
Three Initiatives Together Form the Diversity Program Consortium
Building Infrastructure Leading to Diversity (BUILD)—BUILD is a set of experimental training awards designed to learn how to attract students from diverse backgrounds into the biomedical research workforce and encourage them to become future contributors to the NIH-funded research enterprise. The...
